Cala Health, a company with a wearable device for essential tremor, recently raised $77 million in funding. It plans to expand to more indications and seek more coverage of its device with the funds.
The company started with genetic testing, but expanded to Covid-19 tests and vaccines during the pandemic. It's valuation has tripled since it last raised a funding round valuing it at $1.5 billion in January.
A new report from Relatient, A Data-Driven Guide to Patient Access Succes, highlights how focusing on data accuracy and relevance can enhance the performance of healthcare practices.
Lyra plans to build out its mental health benefits for multinational companies through its existing partnership with ICAS. The company recently passed a $4.6 billion valuation.
Mental health startup Lyra Health raised $187 million in funding, giving it a post-money valuation of about $2.3 billion. The company also struck a partnership with EAP-provider ICAS, which would expand its mental health benefit to employees in other countries.
The company is working to move its CD47-targeting drug, ALX148, into Phase II development. Another company, Forty Seven, is also developing a CD47-targeting therapy. CD47 is an immune checkpoint distinct from the ones targeted by currently marketed cancer immunotherapy drugs.
The partnership builds on an existing relationship between All of Us and Color, which was chosen as one of three genome centers that are responsible for actual genotyping of patient samples.
When it comes to managing inbound phone calls, underperformance has devastating cost implications.
The Burlingame, California-based startup bills itself as a bioelectric medicine company that is using electric signals to stimulate the nervous system as a pathway to treat chronic disease.
The funding will be used towards product development and to expand the number of therapists serving the business from its current level of 2,500.
Color Genomics' latest test highlights the quandary of genetic testing colliding with value-based care: Is the push to test taking preventive medicine in the wrong direction?
Is hereditary cancer screening really worth it for the general population? Increasingly, the answer is 'yes.'
Join us on February 26 at 3 pm ET, and we’ll dive into the key areas where practices are losing time and money and provide solutions to overcome them.
So far Refactor has invested in 20 software companies, half of them supporting healthcare and life sciences.
Cleave Biosciences is trying to prevent protein degradation, a hallmark of certain cancers, in its aim to develop drugs that work on solid tumors and blood cancers.
Lyra Health, a digital health startup co-founded by former Genentech and Facebook CFO Dave Ebersman to improve the patient referral process and care coordination for mental health, has raised a $35 million Series A round, according to a company statement. Greylock Partners and existing investor Venrock led the round designed to boost its clinical and […]